SBMFF (Sino Biopharmaceutical) Moat Score: 6/10 (As of Jul. 04, 2026)


SBMFF Sino Biopharmaceutical Ltd SBMFF
61 GF Score
Price $0.59
GF Value $0.60
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical Moat Score?

Sino Biopharmaceutical SBMFF -1.48% 61 Moat Score is 6 as of Jul. 04, 2026. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,399 Biotechnology companies, Sino Biopharmaceutical ranks better than 98.93% on this metric.

Sino Biopharmaceutical has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sino Biopharmaceutical has Narrow Moat: Sino Biopharmaceutical Ltd has a strong narrow moat due to its valuable intellectual property, significant R&D capabilities, and strong brand in the pharmaceutical industry. However, regulatory challenges and competition prevent it from achieving a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sino Biopharmaceutical might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sino Biopharmaceutical  (OTCPK:SBMFF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sino Biopharmaceutical Moat Score Related Terms

SBMFF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Moat Score distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Moat Score falls into.


SBMFF
61GF Score
Sino Biopharmaceutical Ltd SBMFF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Sino Biopharmaceutical (SBMFF) has a Moat Score of 6 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sino Biopharmaceutical ranks #15 out of 1399 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Sino Biopharmaceutical's Moat Score too high?
Sino Biopharmaceutical's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. Sino Biopharmaceutical's value of 6 is 200% above this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #15 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #15 out of 1399 companies for Moat Score. This places Sino Biopharmaceutical in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Sino Biopharmaceutical's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.60, compared to a current price of $0.59 — trading 1.2% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Moat Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $0.59 is trading 1.2% below its estimated GF Value™ of $0.60. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for SBMFF:

  • Moat Score: 6
  • GF Value™: $0.60 vs. price of $0.59 (1.2% below fair value)
  • GF Score™: 61/100 with 4 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1399)

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score

Get the complete analysis for SBMFF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price
$0.60
GF Value